{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+1+or+Capsule+2&page=2", "query": { "intervention": "Capsule 1 or Capsule 2", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Capsule+1+or+Capsule+2&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-27T11:39:35.353Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00910689", "title": "Drug and Non-Drug Treatment Of Severe Migraine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Migraine Headache" ], "interventions": [ { "name": "Propranolol or nadolol", "type": "DRUG" }, { "name": "Placebo control", "type": "DRUG" }, { "name": "Behavioral Migraine Management (BMM)", "type": "BEHAVIORAL" }, { "name": "Optimal Acute Therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Ohio University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 232, "start_date": "2001-07", "completion_date": "2005-11", "has_results": true, "last_update_posted_date": "2016-11-22", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 2, "location_summary": "Athens, Ohio • Westerville, Ohio", "locations": [ { "city": "Athens", "state": "Ohio" }, { "city": "Westerville", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00910689" }, { "nct_id": "NCT03894540", "title": "Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumor" ], "interventions": [ { "name": "IPN60090", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "IPN60090 single administration", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2019-03-22", "completion_date": "2020-12-21", "has_results": true, "last_update_posted_date": "2022-09-13", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03894540" }, { "nct_id": "NCT00634348", "title": "A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Aripiprazole", "type": "DRUG" }, { "name": "Ziprasidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 256, "start_date": "2004-04", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2021-02-21", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 41, "location_summary": "Anaheim, California • Cerritos, California • Culver City, California + 33 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Culver City", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00634348" }, { "nct_id": "NCT06328738", "title": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2-positive Gastric Cancer", "HER2 Positive Solid Tumors", "HER2 Amplification", "Colorectal Cancer" ], "interventions": [ { "name": "ELVN-002", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Enliven Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2024-05-30", "completion_date": "2028-07", "has_results": false, "last_update_posted_date": "2025-11-19", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 3, "location_summary": "Plantation, Florida • St Louis, Missouri • Fairfax, Virginia", "locations": [ { "city": "Plantation", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT06328738" }, { "nct_id": "NCT04844463", "title": "A Study of JNJ-68179280 in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "JNJ-68179280", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 94, "start_date": "2021-05-26", "completion_date": "2023-03-13", "has_results": false, "last_update_posted_date": "2025-02-03", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04844463" }, { "nct_id": "NCT00903006", "title": "Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Fulvestrant", "type": "DRUG" }, { "name": "MK-0646", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2009-11", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2015-02-02", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00903006" }, { "nct_id": "NCT06106308", "title": "Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "CRC", "KRAS/NRAS Mutation" ], "interventions": [ { "name": "Onvansertib", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cardiff Oncology", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 110, "start_date": "2024-02-27", "completion_date": "2027-01", "has_results": false, "last_update_posted_date": "2026-06-16", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 41, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 35 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06106308" }, { "nct_id": "NCT00455013", "title": "A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Disorder Related to Renal Transplantation" ], "interventions": [ { "name": "Thymoglobulin", "type": "DRUG" }, { "name": "Belatacept", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate Mofetil (MMF)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 93, "start_date": "2007-07", "completion_date": "2012-08", "has_results": true, "last_update_posted_date": "2014-06-09", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 11, "location_summary": "San Francisco, California • Denver, Colorado • Augusta, Georgia + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00455013" }, { "nct_id": "NCT01240460", "title": "Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma", "Astrocytoma, Grade IV" ], "interventions": [ { "name": "XL765 (SAR245409)", "type": "DRUG" }, { "name": "XL147 (SAR245408)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2011-01", "completion_date": "2012-06", "has_results": false, "last_update_posted_date": "2012-07-27", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 4, "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01240460" }, { "nct_id": "NCT01266525", "title": "Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dementia Alzheimer's Type" ], "interventions": [ { "name": "SAR110894", "type": "DRUG" }, { "name": "placebo (for SAR110894)", "type": "DRUG" }, { "name": "Donepezil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 291, "start_date": "2011-02", "completion_date": "2013-01", "has_results": false, "last_update_posted_date": "2016-03-14", "last_synced_at": "2026-09-27T11:39:35.353Z", "location_count": 27, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Costa Mesa", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01266525" } ] }